Relapse and Acquired Rifampin Resistance in HIV-Infected Patients with Tuberculosis Treated with Rifampin- or Rifabutin-Based Regimens in New York City, 1997-2000 | Zendy

Jiehui Li | Zendy; Sonal S. Munsiff | Zendy; Christina Driver | Zendy; Judith E. Sackoff | Zendy

Open Access

Relapse and Acquired Rifampin Resistance in HIV-Infected Patients with Tuberculosis Treated with Rifampin- or Rifabutin-Based Regimens in New York City, 1997-2000

Author(s) -

Jiehui Li,

Sonal S. Munsiff,

Christina Driver,

Judith E. Sackoff

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/430377

Subject(s) - rifabutin , medicine , serostatus , regimen , hazard ratio , tuberculosis , rifamycin , odds ratio , relative risk , rifampicin , retrospective cohort study , confidence interval , surgery , immunology , antibiotics , human immunodeficiency virus (hiv) , viral load , pathology , clarithromycin , microbiology and biotechnology , biology , helicobacter pylori

The relationship between rifamycin use and either relapse or treatment failure with acquired rifampin resistance (ARR) among human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB) is not well understood.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research